See more : QXO Inc (QXO) Income Statement Analysis – Financial Results
Complete financial analysis of Takeda Pharmaceutical Company Limited (TAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Takeda Pharmaceutical Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Shuhua Sports Co., Ltd. (605299.SS) Income Statement Analysis – Financial Results
- Micro Imaging Technology, Inc. (MMTC) Income Statement Analysis – Financial Results
- SCP & CO Healthcare Acquisition Company (SHAC) Income Statement Analysis – Financial Results
- Ellington Financial Inc. (EFC-PC) Income Statement Analysis – Financial Results
- Sanlux Co.,Ltd (002224.SZ) Income Statement Analysis – Financial Results
Takeda Pharmaceutical Company Limited (TAK)
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,263.76B | 4,027.48B | 3,569.01B | 3,197.81B | 3,291.19B | 2,097.22B | 1,770.53B | 1,732.05B | 1,807.38B | 1,777.82B | 1,691.69B | 1,557.27B | 1,508.93B | 1,419.39B | 1,465.97B | 1,538.34B | 1,374.80B | 1,305.17B | 1,212.21B | 1,122.96B | 1,086.43B | 1,046.08B | 1,005.06B | 963.48B | 923.13B |
| Cost of Revenue | 1,431.51B | 1,244.07B | 1,106.85B | 994.31B | 1,089.76B | 659.69B | 495.92B | 558.76B | 535.41B | 520.99B | 490.26B | 447.63B | 433.19B | 317.58B | 285.06B | 289.54B | 278.63B | 279.66B | 282.10B | 279.18B | 269.40B | 300.34B | 337.85B | 384.01B | 432.33B |
| Gross Profit | 2,832.26B | 2,783.41B | 2,462.16B | 2,203.50B | 2,201.42B | 1,437.53B | 1,274.61B | 1,173.30B | 1,271.97B | 1,256.83B | 1,201.42B | 1,109.64B | 1,075.74B | 1,101.80B | 1,180.90B | 1,248.79B | 1,096.17B | 1,025.51B | 930.11B | 843.78B | 817.04B | 745.74B | 667.21B | 579.47B | 490.80B |
| Gross Profit Ratio | 66.43% | 69.11% | 68.99% | 68.91% | 66.89% | 68.54% | 71.99% | 67.74% | 70.38% | 70.70% | 71.02% | 71.26% | 71.29% | 77.63% | 80.55% | 81.18% | 79.73% | 78.57% | 76.73% | 75.14% | 75.20% | 71.29% | 66.38% | 60.14% | 53.17% |
| Research & Development | 729.92B | 633.33B | 526.09B | 455.83B | 492.38B | 368.30B | 325.44B | 312.30B | 345.93B | 382.10B | 341.56B | 324.29B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 499.40B | 450.96B | 811.62B | 810.71B | 640.20B | 666.68B | 834.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 385.96B | 0.00 | 319.36B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.21B | 105.25B | 175.52B | 0.00 | 94.52B | 94.01B | 108.10B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1,053.82B | 997.31B | 886.36B | 875.66B | 964.74B | 717.60B | 628.11B | 619.06B | 650.77B | 612.61B | 556.21B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 385.96B | 0.00 | 319.36B |
| Other Expenses | 834.44B | 662.27B | 588.87B | 362.74B | 643.90B | 908.87B | 707.38B | 705.13B | 795.22B | 1,003.99B | 720.59B | 5.81B | 0.00 | 3.78B | 735.00M | 12.13B | 673.05B | 567.01B | 527.30B | 458.50B | 445.40B | 435.05B | 0.00 | 353.37B | 0.00 |
| Operating Expenses | 2,618.18B | 2,292.90B | 2,001.32B | 1,694.24B | 2,101.02B | 1,277.17B | 1,032.82B | 1,017.43B | 1,141.15B | 1,386.09B | 1,062.15B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | 673.05B | 567.01B | 527.30B | 458.50B | 445.40B | 435.05B | 385.96B | 353.37B | 319.36B |
| Cost & Expenses | 4,049.69B | 3,536.97B | 3,108.16B | 2,688.54B | 3,190.78B | 1,936.86B | 1,528.74B | 1,576.18B | 1,676.55B | 1,907.08B | 1,552.41B | 1,434.76B | 1,243.91B | 1,052.30B | 1,045.75B | 1,231.87B | 951.68B | 846.67B | 809.40B | 737.68B | 714.80B | 735.40B | 723.82B | 737.38B | 751.69B |
| Interest Income | 11.29B | 62.91B | 23.70B | 105.52B | 27.83B | 6.62B | 39.54B | 12.27B | 21.65B | 15.36B | 49.30B | 16.30B | 6.30B | 1.73B | 1.98B | 11.38B | 62.06B | 56.24B | 34.21B | 18.10B | 10.90B | 10.13B | 9.61B | 9.93B | 0.00 |
| Interest Expense | 119.54B | 169.70B | 166.61B | 248.63B | 165.01B | 48.16B | 31.93B | 23.25B | 31.93B | 32.88B | 30.72B | 3.32B | 1.88B | 1.34B | 1.43B | 1.62B | 333.00M | 247.00M | 365.00M | 334.00M | 359.00M | 420.00M | 759.00M | 1.02B | 1.19B |
| Depreciation & Amortization | 728.00B | 664.40B | 583.15B | 559.67B | 583.65B | 247.69B | 182.13B | 171.43B | 181.24B | 260.95B | 215.74B | 201.11B | 150.19B | 106.72B | 114.83B | 118.08B | 31.69B | 28.82B | 28.73B | 31.23B | 28.08B | 29.96B | 28.43B | 33.61B | 33.36B |
| EBITDA | 900.33B | 1,156.46B | 1,183.21B | 983.72B | 880.33B | 464.22B | 359.96B | 296.88B | 349.85B | 148.39B | 368.18B | 351.18B | 421.82B | 479.63B | 537.64B | 518.25B | 608.87B | 654.45B | 547.05B | 472.66B | 474.59B | 462.28B | 402.62B | 297.70B | 237.32B |
| EBITDA Ratio | 21.12% | 30.02% | 29.49% | 36.73% | 20.90% | 17.95% | 24.36% | 22.48% | 19.36% | 8.35% | 23.96% | 22.55% | 27.95% | 34.12% | 36.67% | 28.78% | 44.53% | 48.03% | 43.89% | 42.75% | 44.48% | 42.00% | 38.20% | 30.16% | 27.31% |
| Operating Income | 214.08B | 490.51B | 460.84B | 509.27B | 100.41B | 204.97B | 241.79B | 155.87B | 130.83B | -129.25B | 139.27B | 122.51B | 265.03B | 367.08B | 420.21B | 306.47B | 423.12B | 458.50B | 402.81B | 385.28B | 371.63B | 310.69B | 281.24B | 226.10B | 171.44B |
| Operating Income Ratio | 5.02% | 12.18% | 12.91% | 15.93% | 3.05% | 9.77% | 13.66% | 9.00% | 7.24% | -7.27% | 8.23% | 7.87% | 17.56% | 25.86% | 28.66% | 19.92% | 30.78% | 35.13% | 33.23% | 34.31% | 34.21% | 29.70% | 27.98% | 23.47% | 18.57% |
| Total Other Income/Expenses | -161.28B | -115.42B | -158.27B | -143.03B | -161.16B | -77.36B | -24.58B | -12.52B | -10.29B | -16.18B | -1.60B | 10.56B | -12.55B | 4.49B | -4.38B | 92.08B | 153.72B | 166.88B | 115.15B | 55.82B | 74.51B | 121.21B | 92.18B | 36.97B | 31.32B |
| Income Before Tax | 52.79B | 375.09B | 302.57B | 366.24B | -60.75B | 94.90B | 217.21B | 143.35B | 120.54B | -145.44B | 158.85B | 129.71B | 252.48B | 371.57B | 415.83B | 398.55B | 576.84B | 625.38B | 517.96B | 441.10B | 446.14B | 431.90B | 373.43B | 263.08B | 202.76B |
| Income Before Tax Ratio | 1.24% | 9.31% | 8.48% | 11.45% | -1.85% | 4.52% | 12.27% | 8.28% | 6.67% | -8.18% | 9.39% | 8.33% | 16.73% | 26.18% | 28.37% | 25.91% | 41.96% | 47.92% | 42.73% | 39.28% | 41.07% | 41.29% | 37.15% | 27.30% | 21.96% |
| Income Tax Expense | -91.41B | 58.05B | 72.41B | -9.94B | -105.04B | -14.12B | 30.50B | 27.83B | 37.06B | -2.40B | 49.29B | -3.88B | 125.21B | 121.33B | 115.67B | 161.35B | 218.77B | 285.84B | 201.36B | 160.23B | 157.91B | 157.49B | 134.89B | 114.15B | 81.45B |
| Net Income | 144.07B | 317.02B | 230.06B | 376.01B | 44.24B | 109.13B | 186.89B | 114.94B | 80.17B | -145.78B | 106.66B | 131.24B | 124.16B | 247.87B | 297.74B | 234.39B | 355.45B | 335.81B | 313.25B | 277.44B | 285.26B | 271.76B | 235.66B | 146.86B | 119.63B |
| Net Income Ratio | 3.38% | 7.87% | 6.45% | 11.76% | 1.34% | 5.20% | 10.56% | 6.64% | 4.44% | -8.20% | 6.30% | 8.43% | 8.23% | 17.46% | 20.31% | 15.24% | 25.85% | 25.73% | 25.84% | 24.71% | 26.26% | 25.98% | 23.45% | 15.24% | 12.96% |
| EPS | 91.16 | 204.29 | 147.14 | 240.72 | 28.41 | 56.75 | 119.67 | 73.58 | 51.13 | -92.69 | 67.55 | 94.11 | 78.65 | 157.01 | 188.60 | 144.91 | 209.49 | 193.00 | 176.74 | 156.51 | 160.93 | 153.82 | 133.51 | 83.20 | 67.78 |
| EPS Diluted | 91.16 | 201.94 | 145.87 | 238.96 | 28.25 | 56.43 | 118.78 | 73.13 | 50.86 | -92.69 | 67.47 | 94.09 | 78.63 | 156.98 | 188.57 | 144.90 | 209.49 | 193.00 | 176.74 | 156.51 | 160.93 | 153.82 | 133.51 | 83.20 | 67.78 |
| Weighted Avg Shares Out | 1.58B | 1.55B | 1.56B | 1.56B | 1.56B | 1.92B | 1.56B | 1.56B | 1.57B | 1.57B | 1.58B | 1.58B | 1.58B | 1.58B | 1.58B | 1.62B | 1.70B | 1.74B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Weighted Avg Shares Out (Dil) | 1.58B | 1.57B | 1.58B | 1.57B | 1.57B | 1.93B | 1.57B | 1.57B | 1.58B | 1.57B | 1.58B | 1.58B | 1.58B | 1.58B | 1.58B | 1.62B | 1.70B | 1.74B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego. Takeda's latest research focuses on improving...
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Takeda's ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA...
US FDA approves Takeda's blood disorder therapy
The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients.
Takeda says FDA approves its treatment for colorectal cancer
Pharmaceutical company Takeda 4502, +0.29% said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal cancer.
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-,...
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in...
TAK vs. STVN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Head of Investor Relations Christophe Weber - President and Chief Executive Officer Andy Plump - President of R&D...
Japan's Takeda slashes full-year profit forecast on drug pipeline impairments
Japan's biggest drugmaker Takeda Pharmaceutical on Thursday slashed its full-year profit forecast by 36% as it contends with disappointments in its development pipeline and the loss of patent protection on key products.
Source: https://incomestatements.info
Category: Stock Reports